# US 2024/0269186 A1 · Multilayered blood product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0269186 A1
- Document ID: US20240269186A1
- Status: Published application
- Kind: A1
- Application number: 18/642,442
- Filed: 2024-04-22
- Published: 2024-08-15
- Earliest claimed: 2008-08-22
- Assignees: Reapplix Aps
- Applicants: Reapplix ApS
- Inventors: Rasmus LUNDQUIST; Niels Erik HOLM
- Web page: https://patentgrep.com/patent/US20240269186A1

## CPC

- A61K 35/19: Platelets; Megacaryocytes
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/33: Fibroblasts
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/363: {Fibrinogen}
- A61L 24/106: {Fibrin; Fibrinogen}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- B04B 5/04: Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- C12N 5/0642: {Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells}
- C12N 5/0644: {Platelets; Megakaryocytes}
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- A61L 26/0042: {Fibrin; Fibrinogen}
- A61M 1/029: {Separating blood components present in distinct layers in a container, not otherwise provided for (containers for storing blood or blood components A61J1/05; sampling or analysing blood by separating blood components G01N33/491)}
- B04B 2005/0485: {with a displaceable piston in the centrifuge chamber}
- C12N 2501/905: Hyaluronic acid
- G01N 33/491: {by separating the blood components (G01N15/05 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B04B: CENTRIFUGES (high-speed drum mills B02C19/11; domestic spin driers D06F; analysing, measuring or monitoring physical or chemical properties of samples during centrifuging, see the relevant subclasses for these procedures, e.g. G01N)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A blood product has three consecutive layers that are self-supporting. The first layer of the three consecutive layers has fibrin, the second layer has thrombocytes, and the third layer has leukocytes. The blood product is configured for application to a surgical site that is open so that the third layer is in direct contact with the surgical site.

## Claims

### Claim 1

A blood product, the blood product comprising:
three consecutive layers that are self-supporting;
a first layer of the three consecutive layers comprising fibrin;
a second layer of the three consecutive layers comprising thrombocytes; and
a third layer of the three consecutive layers comprising leukocytes,
wherein the blood product is configured for application to a surgical site that is open so that the third layer is in direct contact with the surgical site.

### Claim 2 (depends on 1)

The blood product according to claim 1, wherein the blood product is flexible to conform to continuous contours to which the blood product is applied.

### Claim 3 (depends on 1)

The blood product according to claim 1, wherein the blood product is flexible to withstand applied stress without rupturing.

### Claim 4 (depends on 1)

The blood product according to claim 1, wherein the three consecutive layers are substantially parallel layers.

### Claim 5 (depends on 1)

The blood product according to claim 1, wherein the first layer comprises the fibrin in a majority by volume of the first layer.

### Claim 6 (depends on 1)

The blood product according to claim 1, wherein the second layer comprises the thrombocytes in a majority by volume of the second layer.

### Claim 7 (depends on 1)

The blood product according to claim 1, wherein the third layer comprises the leukocytes in a majority by volume of the third layer.

### Claim 8 (depends on 1)

The blood product according to claim 1, wherein the first layer comprises the fibrin in a majority by mass of the first layer.

### Claim 9 (depends on 1)

The blood product according to claim 1, wherein the second layer comprises the thrombocytes in a majority by mass of the second layer.

### Claim 10 (depends on 1)

The blood product according to claim 1, wherein the third layer comprises the leukocytes in a majority by mass of the third layer.

### Claim 11 (depends on 1)

The blood product according to claim 1, wherein the first layer comprises the fibrin in a majority by volume and/or mass of the first layer, wherein the second layer comprises the thrombocytes in a majority by volume and/or the second layer, and wherein the third layer comprises the leukocytes in a majority by volume and/or mass of the third layer.

### Claim 12 (depends on 11)

The blood product according to claim 11, wherein the first layer, the second layer, and the third layer are substantially parallel to each other.

### Claim 13 (depends on 1)

The blood product according to claim 1, wherein the blood product consists of components from whole blood.

### Claim 14 (depends on 1)

The blood product according to claim 1, further comprising at least one substance selected from the group consisting of: fibroblasts, keratinocyte cells, and hyaluronic acid.

### Claim 15 (depends on 1)

The blood product according to claim 1, further comprising thrombin or calcium ion.

### Claim 16 (depends on 1)

The blood product according to claim 1, wherein the blood product is autologous.

### Claim 17 (depends on 1)

The blood product according to claim 1, wherein the blood product is configured for sealing a surgical area, preventing post-surgical adherence and/or surgical anastomosing.

### Claim 18 (depends on 1)

A method for stopping bleeding and/or initiating healing of a wound, the method comprising:
applying the blood product according to claim 1 to the wound so that the third layer is in direct contact with the wound.

### Claim 19 (depends on 1, 18)

The method according to claim 18, further comprising, prior to the applying, forming the blood product according to claim 1 autologously.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the wound is a surgical wound.

### Claim 21 (depends on 1)

A method for preventing post-surgical adherence, the method comprising:
applying the blood product according to claim 1 to a surgical wound so that the third layer is in direct contact with the wound.

### Claim 22 (depends on 21)

The method according to claim 21 further comprises forming the blood product according to claim autologously prior to application.

### Claim 23 (depends on 1)

A method for sealing a surgical area, the method comprising:
applying the blood product according to claim 1 to the surgical area, so that the third layer is in direct contact with the surgical area.

### Claim 24 (depends on 1, 23)

The method according to claim 23, further comprising, prior to the applying, forming the blood product according to claim 1 autologously.
